2013
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.
Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, Paltiel AD, Schackman BR. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Annals Of Internal Medicine 2013, 158: 84-92. PMID: 23318310, PMCID: PMC3664029, DOI: 10.7326/0003-4819-158-2-201301150-00002.Peer-Reviewed Original Research
2009
HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost-Effectiveness
Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR, Sloan CE, Sax PE, Walensky RP. HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost-Effectiveness. Clinical Infectious Diseases 2009, 48: 806-815. PMID: 19193111, PMCID: PMC2876329, DOI: 10.1086/597095.Peer-Reviewed Original Research